Objective. To evaluate the efficacy of calcitriol and hormonal replacement therapy (HRT ) in the treatment of steroid-induced osteoporosis in hypogonadal women.
Glucocorticoids are widely used in the treatment of formation and increase in bone resorption [6 ] . The mechanism of bone loss is believed to act through patients with autoimmune and chronic inflammatory inhibition of osteoblastogenesis and promotion of diseases due to their potent immunomodulatory action.
apoptosis of osteoblasts and osteocytes [7] . In recent However, one of the major side-effects which limits the years, a number of studies have demonstrated that the use of this group of agents is the complication on bone adverse effect of glucocorticoid on bone loss can be loss and bone fractures, especially vertebral fractures.
prevented [8] . Active agents include vitamin D and The pathogenesis of steroid-induced osteoporosis is its derivatives, calcitonin and bisphosphonates [8] . complex [1] . These include the reduction in intestinal Initiation of these agents within 4 weeks of steroid calcium absorption [2] , increase in renal calcium excretherapy is effective in preventing bone loss which is tion [3] , secondary hyperparathyroidism [4] , suppresusually most marked within the first year of therapy [9] . sion of gonadotropin release [5] , suppression of bone It has been shown that the effect of these agents is similar in both pre-and post-menopausal women. However, in patients who already have bone loss due the general consensus is to give hormonal replacement Bone densitometry therapy ( HRT ) [10, 11] . However, there are only a few BMD, expressed as an areal density, was measured at studies documenting the effect of HRT in hypogonadal the lumbar spine (L2-4), femoral neck, trochanter, women on chronic steroid therapy [12, 13] . Although Ward's triangle, and distal radius using dual-energy the use of HRT may be effective in preventing bone X-ray absorptiometry (DEXA; Hologic QDR 2000 plus, loss, HRT is known to cause flare up of certain autoHologic, Waltham, MA, USA). The in vivo precision of immune diseases and may be contraindicated, for the machine obtained from five post-menopausal women example, in diseases such as systemic lupus erythmeasured four times over 2 weeks for the lumbar spine, ematosus (SLE ) [14] .
femoral neck, Ward's triangle, and distal one-third The use of non-hormonal agents such as calcitonin, radius was 1.2, 1.5, 2.2 and 1.4%, respectively. The bone bisphosphonates and vitamin D derivatives has been scans were performed by an independent person who reported to give variable benefits in established steroidwas unaware of the treatment the patients were receiving. induced bone loss [10, 11] . Calcitonin injection has been
Results are presented as mean ± .. shown to be effective for primary and secondary prevention of steroid-induced bone loss, but it does not signiLaboratory tests ficantly restore bone mass in the presence of steroids Fasting blood was obtained for laboratory tests. Serum [15] . The use of calcitonin is also constrained by its calcium, phosphorus, albumin, creatinine, total alkaline cost, side-effects, resistance to treatment with the develphosphatase were measured using a Hitachi 747 random opment of antibodies and a lack of efficacy to prevent access analyser (Boehringer, Mannheim, Germany). fractures [16, 17] . Bisphosphonates are effective in Serum intact osteocalcin, a marker of bone formation, increasing lumbar spine and femoral neck bone mineral was measured by enzyme-linked immunosorbent assay density (BMD) in steroid-treated patients when com-( ELISA) method using commercial kits (Novocalcin, pared with controls [18, 19] . However, in view of the Metra Biosystems, Inc., CA, USA). The laboratory long half-life of bisphosphonates, the use of these agents intra-and interassay coefficients of variation were 8.8 in young patients with immature skeletons is still of and 10.1%. Subjects were asked to bring a 24-h urine concern. Calcitriol has been shown to be effective in collection for calcium and creatinine measurement. A primary prevention of bone loss with corticosteroids 2-h fasting morning urine sample was also collected for [20] , but whether it is effective in chronic steroid therapy n-telopeptide (NTx) measurement. Urine NTx, a marker is uncertain. The aim of our project was to evaluate the for bone resorption, was determined by ELISA effectiveness of HRT vs calcitriol in treating young (Osteomark, Ostex, Seattle, WA, USA). The intra-and hypogonadal women with SLE on chronic steroid interassay coefficients of variation were 8.7 and 10.9%, therapy.
respectively. All samples for individual subjects were measured in a single assay.
Patients and methods

Statistical analysis Patients
Baseline values were compared using two-sample Twenty-eight women aged 37 ± 6 yr with SLE [21] on Student's t-test. Results are reported as mean ± .. The chronic steroid therapy were studied. These patients longitudinal data were analysed as the percentage change were put on steroid therapy at the diagnosis of the from baseline and the two groups were compared using disease. All of them were taking at least 10 mg of the ANOVA method. prednisone daily and were on steroid treatment for a mean period of 130 ± 22 (range 30-240) months. They Results were amenorrhoeic for at least 2 yr and proven to have ovarian failure with elevated luteinizing hormone/ BMD data follicular stimulating hormone. All had osteopenia with Table 1 shows the baseline characteristics of the two the T score at L2-4 of less than −1 according to local groups of patients. No differences were observed in their southern Chinese peak young mean values. All of them demographic, biochemical as well as BMD data. There had stable disease and were considered suitable for HRT was no correlation between the BMD values and the treatment.
total steroid dose used and the duration of steroid Methods therapy in these patients. The serial changes of the various BMD results are The patients were randomly assigned to receive either HRT (conjugated oestrogen premarin 0.625 mg daily shown in Fig. 1 . Treatment with HRT resulted in a 2.0 ± 0.4% increase in the lumbar spine BMD from day 1 to day 21 plus medroxyprogesterone acetate 5 mg daily from day 10 to day 21 of the 28 day (P < 0.05). There was no significant change in the BMD at both the hip and the forearm. Women treated with cycle ( Wyeth, USA) or calcitriol (Rocaltrol, Roche Laboratories, USA) 0.5 mg daily. All patients received calcitriol continued to demonstrate bone loss. At the lumbar spine, there was a 1.6 ± 0.4% reduction at calcium carbonate 1 g daily. Biochemical bone markers and BMDs were determined at baseline and every 18 months (P < 0.05 vs baseline) and a 1.74 ± 0.4% reduction at 24 months (P < 0.05 vs baseline). Similarly, 6 months for 2 yr. bone loss was present at the forearm. At the distal oneand bone mineral density (BMD) with treatment third radius, bone loss could be detected as early as 6 months of the study, and by the end of 2 yr there was Baseline values for the biochemical bone markers are shown in Table 1 . Urine NTx showed a 30 ± 57% *P < 0.05, **P < 0.01.
reduction after 6 months of HRT therapy and the values remained suppressed during the 2 yr of treatment. and total hip BMD, their percentage changes at 12 and 24 months were actually correlated with the changes in Contrarily those receiving calcitriol had an 8% increase in NTx excretion at 6 months, and a 53.5% increase NTx at 6 and 12 months ( Table 2) . Serum osteocalcin levels were markedly suppressed at by 24 months. However, the differences observed with both treatment groups were statistically insignificant.
baseline ( local normal reference value for premenopausal women is 3-10 ng/ml ) ( Table 1) . Treatment Grouping all patients together, the changes in NTx at 6 months and 12 months correlated negatively with with both HRT and calcitriol resulted in a significant increase in serum osteocalcin level by 2 yr ( HRT the changes in the lumbar spine at 12 (r = − 0.633, P < 0.005) and 24 months (r = − 0.629, P < 0.005) 9.2 ± 10.4 ng/ml, calcitriol 9.7 ± 6.2 ng/ml, both P < 0.05 vs baseline), and there was no difference in the ( Table 2 , Fig. 2 ). However, in individual patients, the lack of NTx response did not necessarily equate to a serum osteocalcin level between the two groups throughout the study. The changes in serum osteocalcin level lack of BMD increase with treatment. There was a mild correlation between the change in NTx at 6 months correlated significantly with the changes in urine NTx excretion at all time points of the study (r values at 6, with the total radius BMD at 6 months, but the correlation disappeared during longer follow-up. Interestingly, 12, 18 and 24 months were 0.36, 0.44, 0.48, 0.40, respectively, P all <0.05). However, the changes in despite the lack of statistical changes in the trochanter osteocalcin did not correlate with any regional BMD measured.
Urinary calcium excretion increased significantly after treatment with both HRT and calcitriol (both P < 0.05), but those receiving calcitriol had significantly higher calcium excretion (calcitriol 0.31 ± 0.32 mmol/mmol; calcium 0.19 ± 0.10 mmol/mmol at 24 months, P < 0.05). There were five episodes of hypercalcaemia (serum calcium >2.6 mmol/l ) in those receiving calcitriol over the 2 yr of the study, but the serum calcium level returned to normal upon transient withdrawal of the drug.
There was no significant change in SLE disease activity during the study period. None of the studied subjects had reactivation of the disease. No fractures were recorded during the study period.
Discussion
Our results show that HRT but not calcitriol could prevent bone loss in young hypogonadal women on long-term glucocorticoid treatment. The response seen in our women taking HRT was similar to the previous observation of Lukert et al. [12] , who reported an increase in spine BMD of 0.03 g/cm2 after 1 yr in the eight women given oestrogen during prednisone treatment for asthma. Similarly, in another study of postmenopausal women with rheumatoid arthritis, Hall et al. [22] reported, in the 18 HRT-treated patients taking steroids, that lumbar spine BMD increased significantly by 3.75% after 24 months, whereas there was no significant change in the femoral neck BMD in both the the distal one-third radius was 1.2%. As it is difficult to dose, there were five episodes of hypercalcaemia that required short-term withdrawal of the drug. Greater recruit a homogeneous group of patients, the majority of these studies, including the present one, were pereffects on BMD improvement had been observed with a higher dose of calcitriol. In patients with postformed with a small number of subjects. It is important to have a homogeneous group of patients, as the undermenopausal osteoporosis, a significant increase in bone mass was found in patients given higher doses of calcilying disorder may also affect the BMD results, e.g. patients with rheumatoid arthritis and gastrointestinal triol (>0.6 mg/day) when compared with those given lower doses (<0.5 mg/day) [27]. Second, the effect of disease had a greater degree of bone loss compared with other conditions due to associated immobilization and calcitriol was reported to be associated with the fractional absorption of calcium, so that a lower intestinal malabsorption. Our results also confirm a lack of correlation between BMD values and cumulative steroid absorption of calcium was associated with a better response of calcitriol and greater improvement in BMD dose, and that the efficacy of HRT is similar in women with or without coexisting steroid therapy [8] .
[28]. However, since we have demonstrated that the fractional intestinal absorption of calcium in our populaThe role of vitamin D in treating steroid-induced osteoporosis is more controversial. Adachi et al. [24] , tion is approximately 61% [28], which is much higher than that for Caucasian subjects, the use of calcitriol in using 50 000 units of vitamin D 3 per week for primary prevention, found no significant change in the lumbar our Chinese population may be less effective compared with other published reports. Third, although all patients spine after 3 yr when compared with calcium treatment alone. However, Buckley et al. [25] observed that vitwere more than 2 yr post-menopause, some of these women might still be having an accelerated phase of amin D 3 could prevent secondary bone loss in both the lumbar spine and the trochanter in patients with rheumbone loss associated with early menopause which could only be treated adequately by HRT replacement. atoid arthritis who were already receiving low-dose steroids. With Kong is a subtropical area and our studied subjects were all ambulatory, it is very unlikely that they had a 4 weeks of therapy. The subjects included pre-and postmenopausal females as well as male patients with various significant degree of vitamin D deficiency. Our previous study also did not demonstrate vitamin D deficiency in medical conditions. The subjects were given calcitriol (0.5-1.0 mg/day), calcitonin, and varying doses of calambulatory post-menopausal osteoporotic women [29] . In this study, we also evaluated the use of biochemical cium. The results showed that calcitriol, with or without calcitonin, prevented more bone loss at the spine in the bone markers in the prediction of BMD response with treatment. Unlike in post-menopausal osteoporosis, first year than calcium alone. Neither calcitriol nor calcitonin prevented bone loss at the femoral neck and NTx, a marker of bone resorption, was not elevated in these subjects with steroid-induced bone loss. Although distal radius. Withdrawal of calcitriol in the second year was associated with bone loss at the lumbar spine, the change of NTx at 6 and 12 months of treatment correlated with the BMD response at the lumbar spine although the author ascribed this to the effect of a higher steroid dosage in these patients. However, the at 12 and 24 months, the actual magnitude of change in NTx level was small. Besides, the individual response dose of calcitriol used was relatively high and 25% of the subjects taking calcitriol developed hypercalcaemia in NTx varied so that a lack of change in NTx did not necessarily reflect a lack of response to antiresorptive and hypercalciuria.
In our present study, we observed significant bone therapy. The change in osteocalcin, a marker for bone turnover and bone formation, showed no relation to loss at the lumbar spine by 18 months of calcitriol therapy. Significant bone loss was also found in the BMD changes. The overall impression agreed with previous observations that NTx is more sensitive than osteotrabecular bone regions of the distal forearm. No change was observed in the hip and in the cortical bone region calcin as a group in predicting BMD response to antiresorptive therapy [30] . The mean percentage reducat the distal forearm. Despite stimulation of bone turnover with a significant increase in osteocalcin level, tion in NTx with HRT in our present study was less than that observed in non-steroid users, which is calcitriol actually failed to increase bone mass, similar to the previous report by Dyskman et al. [26 ] . However, approximately 50% reduction by 1 yr [30], but the increase in the lumbar spine BMD in our patients was since our study did not have a placebo group, we cannot be certain whether the effect of calcitriol is superior to similar to that observed with non-steroid users.
In conclusion, HRT but not calcitriol could prevent treatment with calcium alone. There are a number of possibilities to explain the findings in the present study.
bone loss in young hypogonadal women on corticosteroid therapy. HRT is a safe treatment for stable SLE First, in order to avoid the side-effects of hypercalcaemia and hypercalciuria of calcitriol, we used a dose of patients and there was no evidence of an adverse effect of HRT on disease activity. Urinary NTx excretion is 0.5 mg/day as recommended [11] . Despite this lower trial of salmon calcitonin to prevent bone loss in corticobetter than serum osteocalcin in reflecting the BMD steroid treated temporal arthritis and polymyalgia rheumresponse to antiresorptive treatment. 
